文献速递主动脉疾病外周动脉疾病

血清微小RNA与腹主动脉瘤诊断及生长的关联

Association Between Serum MicroRNAs and Abdominal Aortic Aneurysm Diagnosis and Growth.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2022-12-31

本研究评估了血清微小RNA(miRNA)与腹主动脉瘤(AAA)诊断及生长的关联。在108例AAA患者、12例健康对照(HC)和12例外周动脉疾病(PAD)患者中评估800个miRNA标签,并在66例AAA和29例HC中验证。联合临床危险因素、let-7b-5p和miR-548n诊断AAA的AUC为98.0%(95%CI 95.6–100.0;p=.003),优于单独临床危险因素(NRI 1.74;95%CI 1.61–1.87;p<.001)。与PAD鉴别时,联合临床危险因素和miR-548n的AUC为99.6%(95%CI 98.9–100.0,p=.037),优于单独临床危险因素(NRI 1.79,95%CI 1.68–1.91;p<.001)。在纵向队列中,无miRNA能比单独临床危险因素更好地预测达到手术阈值直径的可能性。结论:血清let-7b-5p和miR548n显著提高了诊断AAA的能力,但无miRNA在预测AAA生长方面具有独立预后价值。

要点

  • 联合临床危险因素、let-7b-5p和miR-548n诊断AAA的AUC达98.0%,优于单独临床危险因素。
  • 与PAD鉴别时,联合临床危险因素和miR-548n的AUC为99.6%,优于单独临床危险因素。
  • 在纵向队列中,无miRNA能比单独临床危险因素更好地预测达到手术阈值直径。

核心结论

  • 血清let-7b-5p和miR548n显著提高了诊断AAA的能力。
  • 无miRNA在预测AAA生长方面具有独立预后价值。

研究设计与样本

  • 使用NanoString技术在108例AAA患者、12例年龄性别匹配的健康对照(HC)和12例外周动脉疾病(PAD)患者中评估800个miRNA标签的表达水平。
  • 在66例AAA患者和29例年龄性别匹配的HC独立样本中通过逆转录聚合酶链反应验证发现。
  • 通过中位3次(四分位距[IQR] 2,3)重复超声扫描评估AAA生长,中位随访1.1年(IQR 1.0,2.0)。
  • 采用回归和线性混合效应分析检验miRNA与AAA诊断及生长的关联,并使用受试者工作特征曲线下面积(AUC)、净重分类指数(NRI)和Cox风险分析评估诊断和预后潜力。

主要发现

  • 与HC相比,联合临床危险因素、let-7b-5p和miR-548n诊断AAA的AUC为98.0%(95%CI 95.6–100.0;p=.003),较单独临床危险因素显著改善(NRI 1.74;95%CI 1.61–1.87;p<.001)。
  • 与PAD相比,联合临床危险因素和miR-548n诊断AAA的AUC为99.6%(95%CI 98.9–100.0,p=.037),较单独临床危险因素显著改善(NRI 1.79,95%CI 1.68–1.91;p<.001)。
  • 在纵向队列中,无miRNA能比单独临床危险因素更好地预测达到手术阈值直径的可能性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to examine the association between serum microRNAs (miRNAs) and diagnosis and growth of abdominal aortic aneurysm (AAA), and to test their diagnostic and prognostic value. METHODS: The expression levels of 800 miRNA tags were assessed in 108 patients with AAA, 12 age and sex matched healthy controls (HCs), and 12 patients with peripheral artery disease (PAD) using NanoString technology. Findings were assessed in an independent sample of 66 patients with AAA and 29 age and sex matched HCs by reverse transcriptase polymerase chain reaction. AAA growth was assessed by a median of three (interquartile range [IQR] 2, 3) repeat ultrasound scans over a median follow up of 1.1 (IQR 1.0, 2.0) years. The association between the miRNA and AAA diagnosis and growth was examined by regression and linear mixed effects analyses. The diagnostic and prognostic potential of the miRNAs were examined using area under the receiver operator characteristic curve (AUC), net re-classification index (NRI), and Cox hazard analyses. RESULTS: In comparison with HCs, a model combining clinical risk factors, let-7b-5p and miR-548n had an AUC of 98.0% (95% confidence interval [CI] 95.6 - 100.0; p = .003) for diagnosing AAA, which was a significant improvement over clinical risk factors alone (NRI 1.74; 95% CI 1.61 - 1.87; p < .001). Compared with PAD, a model combining clinical risk factors and miR-548n had an AUC of 99.6% (95% CI 98.9 - 100.0, p = .037) for diagnosing AAA, which was a significant improvement over clinical risk factors alone (NRI 1.79, 95% CI 1.68 - 1.91; p < .001). In the longitudinal cohort, none of the miRNAs were able to predict the likelihood of reaching surgical threshold diameter better than clinical risk factors alone. CONCLUSION: Serum let-7b-5p and miR548n significantly improved the ability to diagnose AAA. None of the miRNAs had independent prognosis value in predicting AAA growth.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Thanigaimani S, Iyer V, Bingley J, et al. Association Between Serum MicroRNAs and Abdominal Aortic Aneurysm Diagnosis and Growth. Eur J Vasc Endovasc Surg. 2022. PMID: 36596338. doi:10.1016/j.ejvs.2022.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。